CryoPort (NASDAQ:CYRX - Get Free Report)'s stock had its "sell (d+)" rating reaffirmed by equities researchers at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.
Other equities analysts also recently issued reports about the company. Leerink Partners upgraded CryoPort from a "market perform" rating to an "outperform" rating and set a $16.00 price target on the stock in a research note on Wednesday, August 6th. KeyCorp upgraded CryoPort from a "sector weight" rating to an "overweight" rating and set a $15.00 price target on the stock in a research note on Wednesday, August 6th. Stephens initiated coverage on CryoPort in a research note on Tuesday, July 22nd. They issued an "overweight" rating and a $13.00 price target on the stock. BTIG Research raised their price target on CryoPort from $10.00 to $15.00 and gave the stock a "buy" rating in a research note on Thursday, September 18th. Finally, Leerink Partnrs upgraded CryoPort from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, CryoPort has a consensus rating of "Moderate Buy" and an average price target of $12.56.
View Our Latest Report on CryoPort
CryoPort Stock Up 2.7%
Shares of CryoPort stock traded up $0.26 on Wednesday, reaching $10.06. The company's stock had a trading volume of 351,526 shares, compared to its average volume of 588,856. The company has a market capitalization of $503.70 million, a price-to-earnings ratio of 7.56 and a beta of 1.61. The firm's fifty day simple moving average is $8.97 and its two-hundred day simple moving average is $7.35. CryoPort has a 52 week low of $4.58 and a 52 week high of $10.46. The company has a quick ratio of 15.47, a current ratio of 16.24 and a debt-to-equity ratio of 0.39.
CryoPort (NASDAQ:CYRX - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.09). The business had revenue of $45.45 million during the quarter, compared to the consensus estimate of $41.74 million. CryoPort had a negative return on equity of 9.79% and a net margin of 37.21%. CryoPort has set its FY 2025 guidance at EPS. Equities analysts anticipate that CryoPort will post -0.99 earnings per share for the current year.
Insider Buying and Selling at CryoPort
In other CryoPort news, Director Ramkumar Mandalam sold 40,728 shares of the firm's stock in a transaction dated Tuesday, July 22nd. The stock was sold at an average price of $7.24, for a total transaction of $294,870.72. Following the sale, the director directly owned 92,328 shares of the company's stock, valued at $668,454.72. This trade represents a 30.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Robert Stefanovich sold 9,300 shares of the firm's stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $8.67, for a total value of $80,631.00. Following the sale, the chief financial officer directly owned 207,213 shares in the company, valued at approximately $1,796,536.71. This represents a 4.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 80,028 shares of company stock valued at $661,252 over the last ninety days. 10.00% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On CryoPort
Large investors have recently made changes to their positions in the company. Rhumbline Advisers increased its holdings in shares of CryoPort by 23.8% in the first quarter. Rhumbline Advisers now owns 78,320 shares of the company's stock worth $476,000 after purchasing an additional 15,036 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in shares of CryoPort by 154.5% in the first quarter. Russell Investments Group Ltd. now owns 32,761 shares of the company's stock worth $199,000 after purchasing an additional 19,886 shares during the last quarter. CWM LLC increased its holdings in shares of CryoPort by 1,437.0% in the first quarter. CWM LLC now owns 11,328 shares of the company's stock worth $69,000 after purchasing an additional 10,591 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of CryoPort by 7.3% in the second quarter. Assenagon Asset Management S.A. now owns 1,090,511 shares of the company's stock worth $8,135,000 after purchasing an additional 73,949 shares during the last quarter. Finally, Readystate Asset Management LP increased its holdings in shares of CryoPort by 91.6% in the first quarter. Readystate Asset Management LP now owns 500,344 shares of the company's stock worth $3,042,000 after purchasing an additional 239,153 shares during the last quarter. 92.90% of the stock is owned by institutional investors.
CryoPort Company Profile
(
Get Free Report)
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CryoPort, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CryoPort wasn't on the list.
While CryoPort currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.